Amplia Therapeutics – Quarterly Activities and Cash Flow Reports – December 2025
Amplia Therapeutics – Quarterly Activities and Cash Flow Reports – December 2025 GlobeNewswire January 30, 2026 Melbourne, Australia, Jan. 30, 2026 (GLOBE NEWSWIRE) — Key Highlights from the Quarter ACCENT Trial Success: The ACCENT trial, testing narmafotinib with gemcitabine and Abraxane(R), continues to demonstrate that narmafotinib is well tolerated by patients whilst enhancing the effects […]